Skip to main content

Advertisement

SpringerLink
Log in

Pediatric applications of Dotatate: early diagnostic and therapeutic experience

  • Review
  • Published:
Pediatric Radiology Aims and scope Submit manuscript

Abstract

In recent years, new somatostatin receptor agents (SSTRs) have become available for diagnostic imaging and therapy in neuroendocrine tumors. The novel SSTR ligand DOTA-DPhel-Tyr3-octreotate (Dotatate) in particular can be linked with 68Gallium for diagnostic imaging purposes, and with the β-emitter 177Lutetium for radiotherapy in the setting of neuroendocrine tumors. Dotatate imaging offers distinct advantages in the evaluation of neuroendocrine tumors compared to standard techniques, including greater target-to-background ratio and lesion conspicuity, high sensitivity/specificity, improved spatial resolution with positron emission tomography (PET)/CT or PET/MR, and decreased radiation exposure. Although currently off-label in pediatrics, Dotatate theranostics in children are being explored, most notably in the setting of neuroblastoma and hereditary neuroendocrine syndromes. This article provides a multicenter case series of Dotatate imaging and therapy in pediatric patients in order to highlight the spectrum of potential clinical applications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13
Fig. 14
Fig. 15
Fig. 16
Fig. 17
Fig. 18
Fig. 19

Similar content being viewed by others

References

  1. Advanced Accelerator Applications (2016) NETSPOT prescribing information. Initial U.S. approval 2016. https://s3-eu-west-1.amazonaws.com/s3-adacap-product/wp-content/uploads/2020/01/02132418/nda208547-pi-20191011.pdf. Accessed 18 Dec 2019

  2. Virgolini I, Ambrosini V, Bomanji J et al (2010) Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 37:2004–2010

    Article  PubMed  Google Scholar 

  3. Advanced Accelerator Applications (2018) LUTATHERA prescribing information. Initial U.S. approval 2018. https://s3-eu-west-1.amazonaws.com/s3-adacap-product/wp-content/uploads/2018/11/30140531/LUTATHERA_lutetium_Lu_177_dotatate_FDA_Prescribing_Information1.pdf. Accessed 18 Dec 2019

  4. Zaknun J, Bodei L, Mueller-Brand J et al (2013) The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging 40:800–816

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Alexander N, Vali R, Ahmadzadehfar H et al (2018) Review: the role of radiolabeled DOTA-conjugated peptides for imaging and treatment of childhood neuroblastoma. Curr Radiopharm 11:14–21

    Article  CAS  PubMed  Google Scholar 

  6. Kruhlich L, Dhariwal A, McCann S (1968) Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 83:783–790

    Article  Google Scholar 

  7. Mojtahedi A, Thamake S, Tworowska I et al (2014) The value of 68Ga-Dotatate PET-CT in diagnosis and management of neuroendocrine tumors compared to FDA approved imaging modalities: a review of literature. Am J Nucl Med Mol Imaging 4:426–434

    PubMed  PubMed Central  Google Scholar 

  8. Krenning E, Kwekkeboom D, Bakker W et al (1993) Somatostatin receptor scintigraphy with (111In-DTPA-D-Phe1)- and (123ITyr3)-octreotide: the Rotterdam experience with more than 1,000 patients. Eur J Nucl Med 20:716–731

    Article  CAS  PubMed  Google Scholar 

  9. Albers A, O’Dorisioa S, Balstera D et al (2000) Somatostatin receptor gene expression in neuroblastoma. Regul Pept 88:61–73

    Article  CAS  PubMed  Google Scholar 

  10. Pauwels E, Cleeren F, Bormans G, Deroose C (2018) Somatostatin receptor PET ligands — the next generation for clinical practice. Am J Nucl Med Mol Imaging 8:311–331

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Hofman M, Kong G, Neels O et al (2012) High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol 56:40–47

    Article  PubMed  Google Scholar 

  12. Srirajaskanthan R, Kayani I, Quigley A et al (2010) The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med 51:875–882

    Article  CAS  PubMed  Google Scholar 

  13. Maurice J, Troke R, Win Z et al (2012) A comparison of the performance of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 39:1266–1270

    Article  CAS  PubMed  Google Scholar 

  14. Naji M, Zhao C, Welsh S et al (2011) 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol 13:769–775

    Article  PubMed  Google Scholar 

  15. Hartmann H, Zophel K, Freudenberg R et al (2009) Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations. Nuklearmedzin 48:201–207

    Article  CAS  Google Scholar 

  16. Hofman M, Lau W, Hicks R (2015) Somatostatin receptor imaging with 68Ga Dotatate PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 35:500–516

    Article  PubMed  Google Scholar 

  17. Krenning E, Bakker W, Breeman W et al (1989) Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1:242–244

    Article  CAS  PubMed  Google Scholar 

  18. Kulke MH, Shah MH, Benson AB 3rd et al (2015) Neuroendocrine tumors, version 1.2015. J Natl Compr Cancer Netw 13:78–108

    Article  CAS  Google Scholar 

  19. Dasari A, Shen C, Halperin D et al (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3:1335–1342

    Article  PubMed  PubMed Central  Google Scholar 

  20. Massironi S, Sciola V, Peracchi M et al (2008) Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol 14:5377–5384

    Article  PubMed  PubMed Central  Google Scholar 

  21. Loh K, Waser B, Tan L et al (2002) Somatostatin receptors in nasopharyngeal carcinoma. Virchows Arch 441:444–448

    Article  CAS  PubMed  Google Scholar 

  22. Heck J, Ritz B, Hung R et al (2008) The epidemiology of neuroblastoma. Paediatr Perinat Epidemiol 23:125–143

    Article  Google Scholar 

  23. Mueller W, Coppenrath E, Pfluger T (2013) Nuclear medicine and multimodality imaging of pediatric neuroblastoma. Pediatr Radiol 43:418–427

    Article  PubMed  Google Scholar 

  24. Maris J, Hogarty M, Bagatell R, Cohn S (2007) Neuroblastoma. Lancet 369:2106–2120

    Article  CAS  PubMed  Google Scholar 

  25. Dumba M, Jawad N, McHugh K (2015) Neuroblastoma and nephroblastoma: a radiological review. Cancer Imaging 15:1–14

    Article  Google Scholar 

  26. Sharp S, Trout A, Weiss B, Gelfand M (2016) MIBG in neuroblastoma diagnostic imaging and therapy. Radiographics 36:258–278

    Article  PubMed  Google Scholar 

  27. Hofman M, Hicks R (2012) Changing paradigms with molecular imaging of neuroendocrine tumors. Discov Med 14:71–81

    PubMed  Google Scholar 

  28. Kroiss A, Putzer D, Uprimny C et al (2011) Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging 38:865–873

    Article  CAS  PubMed  Google Scholar 

  29. Kong G, Hofman M, Murray W et al (2016) Initial experience with gallium-68 DOTA-octreotate PET/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma. J Pediatr Hematol Oncol 38:87–96

    Article  CAS  PubMed  Google Scholar 

  30. Torun N (2019) 68Ga-DOTA-TATE in neuroblastoma with marrow involvement. Clin Nucl Med 44:467–468

    Article  PubMed  Google Scholar 

  31. Goel R, Shukla J, Bansal D et al (2014) 68Ga-DOTATATE positron emission tomography/computed tomography scan in the detection of bone metastases in pediatric neuroendocrine tumors. Indian J Nucl Med 29:13–17

    Article  PubMed  PubMed Central  Google Scholar 

  32. Fiani B, Quadri S, Cathel A et al (2019) Esthesioneuroblastoma: a comprehensive review of diagnosis, management, and current treatment options. World Neurosurg 126:194–211

    Article  PubMed  Google Scholar 

  33. Sheehan J, Payne R (2016) Esthesioneuroblastomas. In: Winn H (ed) Youmans and Winn neurological surgery e-book. Elsevier Health Sciences, New York, pp 1284–1292

    Google Scholar 

  34. Czapiewski P, Kunc M, Gorczynski A et al (2018) Frequent expression of somatostatin receptor 2a in olfactory neuroblastomas: a new and distinctive feature. Hum Pathol 79:144–150

    Article  CAS  PubMed  Google Scholar 

  35. Bosman F, Carneiro F, Hruban R et al (2010) WHO classification of tumours of the digestive system, 4th edn. IARC, Lyon

    Google Scholar 

  36. Vlajkovic M, Rajic M, Stevic M et al (2012) Clinical role of somatostatin analogues scintigraphy in patients with carcinoid tumors. J Nucl Med 53:2113

    Google Scholar 

  37. Broaddus R, Herzog C, Hicks M (2003) Neuroendocrine tumors (carcinoids and neuroendocrine carcinoma) presenting at extra-appendiceal sites in childhood and adolescence. Arch Pathol Lab Med 127:1200–1203

    PubMed  Google Scholar 

  38. Parkes S, Muir K, Al Sheyyab M et al (1993) Carcinoid tumors of the appendix in children 1957-1986: incidence, treatment and outcome. Br J Surg 80:502–504

    Article  CAS  PubMed  Google Scholar 

  39. Schembri G, Hain S, Roach P (2015) Value of Gallium-68 Dotatate PET scan in staging patients with appendiceal carcinoid tumour: a case series. J Nucl Med 56:1660

    Google Scholar 

  40. Granberg D, Sundin A, Janson E et al (2003) Octreoscan in patients with bronchial carcinoid tumors. Clin Endocrinol 59:793–799

    Article  Google Scholar 

  41. Yellin A, Zwas S, Rozenman J et al (2005) Experience with somatostatin receptor scintigraphy in the management of pulmonary carcinoid tumors. Isr Med Assoc J 7:712–716

    PubMed  Google Scholar 

  42. Musi M, Carbone R, Bertocci C et al (1988) Bronchial carcinoid tumours: a study on clinicopathologic features and role of octreotide scintigraphy. Lung Cancer 22:97–102

    Article  Google Scholar 

  43. Lococo F, Cesario A, Paci M et al (2014) PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids. Tumor Biol 35:8369–8377

    Article  CAS  Google Scholar 

  44. Tan T, Hussein Z, Saad F, Shuaib I (2015) Diagnostic performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT and 131I-MIBG scintigraphy in mapping metastatic pheochromocytoma and paraganglioma. Nucl Med Mol Imaging 49:143–151

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Chang C, Pattison D, Tothill R et al (2016) 68Ga-DOTATATE and 18F-FDG PET/CT in paraganglioma and pheochromocytoma: utility, patterns and heterogeneity. Cancer Imaging 16:22

    Article  PubMed  PubMed Central  Google Scholar 

  46. Jha A, Ling A, Millo C et al (2018) Superiority of 68Ga-DOTATATE over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population. Eur J Nucl Med Mol Imaging 45:787–797

    Article  CAS  PubMed  Google Scholar 

  47. Thakker R, Newey P, Walls G et al (2012) Clinical practice guidelines for multiple endocrine neoplasia Type 1 (MEN1). J Clin Endocrinol Metab 97:2990–3011

    Article  CAS  PubMed  Google Scholar 

  48. Giusti F, Marini F, Brandi M (2019) Multiple endocrine neoplasia Type 1. GeneReviews. https://www.ncbi.nlm.nih.gov/books/NBK1538/. Accessed 18 Dec 2019

  49. Brandi M, Gagel RF, Angeli A et al (2001) Guidelines for diagnosis and therapy of MEN Type 1 and Type 2. J Clin Endocrinol Metab 86:5658–5671

    Article  CAS  PubMed  Google Scholar 

  50. Eng C (2019) Multiple endocrine neoplasia Type 2. GeneReviews. https://www.ncbi.nlm.nih.gov/books/NBK1257/. Accessed 18 Dec 2019

  51. Wohlk N, Schweizer H, Erlic Z et al (2010) Multiple endocrine neoplasia Type 2. Best Pract Res Clin Endocrinol Metab 24:371–387

    Article  CAS  Google Scholar 

  52. Asgharian B, Chen Y, Patronas N et al (2004) Meningiomas may be a component tumor of multiple endocrine neoplasia Type 1. Clin Cancer Res 10:869–880

    Article  CAS  PubMed  Google Scholar 

  53. Thakker R (2010) Multiple endocrine neoplasia Type 1 (MEN1). Best Pract Res Clin Endocrinol Metab 24:355–370

    Article  CAS  PubMed  Google Scholar 

  54. Trouillas J, Labat-Moleur F, Sturm N et al (2008) Pituitary tumors and hyperplasia in multiple endocrine neoplasia Type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2,509 non-MEN1 patients. Am J Surg Pathol 32:534–543

    Article  PubMed  Google Scholar 

  55. Gibril F, Venzon D, Ojeaburu J et al (2001) Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab 86:5282–5293

    Article  CAS  PubMed  Google Scholar 

  56. Thomas-Marques L, Murat A, Delemer B et al (2006) Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia Type 1. Am J Gastroenterol 101:266–273

    Article  PubMed  Google Scholar 

  57. Kann P, Balakina E, Ivan D et al (2006) Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia Type 1: an endoscopic ultrasound imaging study. Endocr Relat Cancer 13:1195–1202

    Article  CAS  PubMed  Google Scholar 

  58. Verges B, Boureille F, Goudet P et al (2002) Pituitary disease in MEN Type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 87:457–465

    Article  CAS  PubMed  Google Scholar 

  59. Lefebvre M, Foulkes W (2014) Pheochromocytoma and paraganglioma syndromes: genetics and management update. Curr Oncol 21:8–17

    Article  Google Scholar 

  60. Scarsbrook A, Thakker R, Wass J et al (2006) Multiple endocrine neoplasia: spectrum of radiologic appearances and discussion of a multitechnique imaging approach. Radiographics 26:433–451

    Article  PubMed  Google Scholar 

  61. Skinner M, DeBenedetti M, Moley J et al (1996) Medullary thyroid carcinoma in children with multiple endocrine neoplasia Types 2A and 2B. J Pediatr Surg 31:177–181

    Article  CAS  PubMed  Google Scholar 

  62. Brauckhoff M, Machens A, Hess S et al (2008) Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: an exploratory analysis. Surgery 144:1044–1050

    Article  PubMed  Google Scholar 

  63. Rednam S, Erez A, Druker H et al (2017) Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 23:e68–e75

    Article  CAS  PubMed  Google Scholar 

  64. Neumann H, Young W, Eng C (2019) Pheochromocytoma and paraganglioma. N Engl J Med 381:552–565

    Article  CAS  PubMed  Google Scholar 

  65. Else T, Greenberg S, Fishbein L (2008) Hereditary paraganglioma–pheochromocytoma syndromes. GeneReviews. https://www.ncbi.nlm.nih.gov/books/NBK1548/. Accessed 18 Dec 2019

  66. Lenders J, Duh Q, Eisenhofer G et al (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:1915–1942

    Article  CAS  PubMed  Google Scholar 

  67. Hes F, Feldberg M (1999) Von Hippel-Lindau disease: strategies in early detection (renal-, adrenal-, pancreatic masses). Eur Radiol 9:598–610

    Article  CAS  PubMed  Google Scholar 

  68. Chittiboina P, Lonser R (2015) Von Hippel-Lindau disease. Handb Clin Neurol 132:139–156

    Article  PubMed  PubMed Central  Google Scholar 

  69. Leung R, Biswas S, Duncan M, Rankin S (2008) Imaging features of von Hippel-Lindau disease. Radiographics 28:65–79

    Article  PubMed  Google Scholar 

  70. Karsdorp N, Elderson A, Wittebol-Post D et al (1994) Von Hippel Lindau disease: new strategies in early detection and treatment. Am J Med 97:158–168

    Article  CAS  PubMed  Google Scholar 

  71. Taouli B, Ghouadni M, Corréas J et al (2003) Spectrum of abdominal imaging findings in von Hippel-Lindau disease. AJR Am J Roentgenol 181:1049–1054

    Article  PubMed  Google Scholar 

  72. Friedman J (2019) Neurofibromatosis 1. GeneReviews. https://www.ncbi.nlm.nih.gov/books/NBK1109/. Accessed 18 Dec 2019

  73. Williams V, Lucas J, Babcock M et al (2009) Neurofibromatosis Type 1 revisited. Pediatrics 123:124–133

    Article  PubMed  Google Scholar 

  74. Friedman J, Arbiser J, Epstein J et al (2002) Cardiovascular disease in Neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genitourin Med 4:105–111

    Article  CAS  Google Scholar 

  75. Howe J, Norton J, Wells S (1993) Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia Type 2A: results of long-term follow-up. Surgery 114:1070–1077

    CAS  PubMed  Google Scholar 

  76. Moline J, Eng C (2011) Multiple endocrine neoplasia Type 2: an overview. Genet Med 13:755–764

    Article  CAS  PubMed  Google Scholar 

  77. Alrezk R, Suarez A, Tena I, Pacak K (2018) Update of pheochromocytoma syndromes: genetics, biochemical evaluation, and imaging. Front Endocrinol 9:515

    Article  Google Scholar 

  78. Tufton N, Sahdev A, Akker S (2017) Radiological surveillance screening in asymptomatic succinate dehydrogenase mutation carriers. J Endocr Soc 1:897–907

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Mukherjee A, Karunanithi S, Bal C, Kumar R (2014) 68Ga DOTANOC PET/CT aiding in the diagnosis of Von Hippel-Lindau syndrome by detecting cerebellar hemangioblastoma and adrenal pheochromocytoma. Clin Nucl Med 39:920–921

    Article  PubMed  Google Scholar 

  80. Prasad V, Tiling N, Denecke T et al (2016) Potential role of 68Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease. Eur J Nucl Med Mol Imaging 43:2014–2020

    Article  CAS  PubMed  Google Scholar 

  81. Papadakis G, Millo C, Jassel I et al (2017) 18F-FDG and 68Ga-DOTATATE PET/CT in von Hippel-Lindau disease-associated retinal hemangioblastoma. Clin Nucl Med 42:189–190

    Article  PubMed  Google Scholar 

  82. Papadakis G, Millo C, Sadowski S et al (2016) Kidney tumor in a von Hippel-Lindau (VHL) patient with intensely increased activity on 68Ga-DOTA-TATE PET/CT. Clin Nucl Med 41:970–971

    Article  PubMed  PubMed Central  Google Scholar 

  83. Stewart D, Korf B, Nathanson K et al (2018) Care of adults with neurofibromatosis Type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med 20:671–682

    Article  PubMed  Google Scholar 

  84. Strosberg J, Wolin E, Chasen B et al (2016) NETTER-1 Phase III in patients with midgut neuroendocrine tumors treated with 177Lu-DOTATATE: efficacy and safety results. J Nucl Med 57:629

    Google Scholar 

  85. Bleeker G, Tygat G, Adam J et al (2015) 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma. Cochrane Database Syst Rev 9:CD009263

    Google Scholar 

  86. Gains J, Bomanji J, Fersht N et al (2011) 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J Nucl Med 52:1041–1047

    Article  PubMed  Google Scholar 

  87. Menda Y, O'Dorisio M, Kao S et al (2010) Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors. J Nucl Med 51:1524–1531

    Article  PubMed  Google Scholar 

  88. Zhu W, Zhang J, Singh A et al (2019) Metastatic nasopharyngeal carcinoma treated with intraarterial combined with intravenous peptide receptor radionuclide therapy. Clin Nucl Med 44:989–990

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA

    Kevin M. McElroy & Larry A. Binkovitz

  2. Department of Radiology, Cincinnati Children’s Hospital Medical Center, University of Cincinnati Medical Center, Cincinnati, OH, USA

    Andrew T. Trout

  3. Tomayko Group, Pittsburgh, PA, USA

    Michael R. Czachowski

  4. Department of Radiology, Texas Children’s Hospital, Houston, TX, USA

    Victor J. Seghers

  5. Department of Endocrinology, Mayo Clinic, Rochester, MN, USA

    Aida N. Lteif

  6. Department of Radiology, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

    Lisa J. States

Authors
  1. Kevin M. McElroy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Larry A. Binkovitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrew T. Trout
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael R. Czachowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Victor J. Seghers
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Aida N. Lteif
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lisa J. States
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Larry A. Binkovitz.

Ethics declarations

Conflicts of interest

None

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

CME activity

This article has been selected as the CME activity for the current month. Please visit the SPR website at www.pedrad.org on the Education page and follow the instructions to complete this CME activity.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McElroy, K.M., Binkovitz, L.A., Trout, A.T. et al. Pediatric applications of Dotatate: early diagnostic and therapeutic experience. Pediatr Radiol 50, 882–897 (2020). https://doi.org/10.1007/s00247-020-04688-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00247-020-04688-z

Keywords

Search

Navigation